contents
TRANSCRIPT
Radiotherapy and Oncology, 2012, Volume 105, Issue 1, October, pp. 1–144
CONTENTSCited in: Chemical Abstracts, Excerpta Medica (EMBASE), Current Contents (Clinical Medicine; Life Sciences), Index Medicus (MEDLINE),
Current Awareness in Biological Sciences (CABS), Full text available on SciVerse ScienceDirect�
Editorial
A community call for a dedicated radiobiological research facility to support particle beam cancer therapyM.H. Holzscheiter, N. Bassler, M. Dosanjh, B.S. Sørensen, J. Overgaard (USA, Denmark, Switzerland) 1
Systematic review
QA makes a clinical trial stronger: Evidence-based medicine in radiation therapyD.C. Weber, M. Tomsej, C. Melidis, C.W. Hurkmans (Switzerland, Belgium, The Netherlands) 4
RTOG guidelines
Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trialsC.G. Willett, J. Moughan, E. O�Meara, J.M. Galvin, C.H. Crane, K. Winter, D. Manfredi, T.A. Rich, R. Rabinovitch, R. Lustig, M. Machtay, W.J. Curran(United States) 9
PET imaging of hypoxia
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from theDAHANCA 24 trialL.S. Mortensen, J. Johansen, J. Kallehauge, H. Primdahl, M. Busk, P. Lassen, J. Alsner, B.S. Sørensen, K. Toustrup, S. Jakobsen, J. Petersen,H. Petersen, J. Theil, M. Nordsmark, J. Overgaard (Denmark) 14
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neckcancerD. Zips, K. Zöphel, N. Abolmaali, R. Perrin, A. Abramyuk, R. Haase, S. Appold, J. Steinbach, J. Kotzerke, M. Baumann (Germany) 21
Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: A comparison with OxyLite, EPR oximetry and 19F-MRI relaxometryL.-B.-A. Tran, A. Bol, D. Labar, B. Jordan, J. Magat, L. Mignion, V. Grégoire, B. Gallez (Belgium) 29
PET imaging
Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynxM.J. Nyflot, P.M. Harari, S. Yip, S.B. Perlman, R. Jeraj (USA) 36
Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: An exploratory studyS.R. Bowen, R.J. Chappell, S.M. Bentzen, M.A. Deveau, L.J. Forrest, R. Jeraj (USA, Slovenia) 41
Tumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferationand 18F-fluorothymidine uptakeM. Axente, J. He, C.P. Bass, J.I. Hirsch, G. Sundaresan, J. Williamson, J. Zweit, A. Pugachev (USA) 49
Hypoxia
Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivoX. Sun, L. Xing, X. Deng, H.T. Hsiao, A. Manami, J.A. Koutcher, C. Clifton Ling, G.C. Li (China, USA) 57
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: A rationale for combination with radiationtherapyO. Karroum, J. Kengen, P. Danhier, J. Magat, L. Mignion, C. Bouzin, J. Verrax, N. Charette, P. Starkel, P.B. Calderon, P. Sonveaux, O. Feron,V. Grégoire, B. Gallez, B.F. Jordan (Belgium) 64
Vascular abnormalities associated with acute hypoxia in human melanoma xenograftsT.G. Simonsen, J.-V. Gaustad, M.N. Leinaas, E.K. Rofstad (Norway) 72
ALLEGRO project
Biological mechanisms of normal tissue damage: Importance for the design of NTCP modelsK.-R. Trott, W. Doerr, A. Facoetti, J. Hopewell, J. Langendijk, P. van Luijk, A. Ottolenghi, V. Smyth (Italy, UK, Germany, The Netherlands) 79
Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia andsticky saliva: The role of dosimetric and clinical factorsI. Beetz, C. Schilstra, F.R. Burlage, P.W. Koken, P. Doornaert, H.P. Bijl, O. Chouvalova, C.R. Leemans, G.H. de Bock, M.E.M.C. Christianen,B.F.A.M. van der Laan, A. Vissink, R.J.H.M. Steenbakkers, J.A. Langendijk (The Netherlands) 86
External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva amongpatients treated with intensity modulated radiotherapyI. Beetz, C. Schilstra, P. van Luijk, M.E.M.C. Christianen, P. Doornaert, H.P. Bijl, O. Chouvalova, E.R. van den Heuvel, R.J.H.M. Steenbakkers,J.A. Langendijk (The Netherlands) 94
NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer:The role of dosimetric and clinical factorsI. Beetz, C. Schilstra, A. van der Schaaf, E.R. van den Heuvel, P. Doornaert, P. van Luijk, A. Vissink, B.F.A.M. van der Laan, C.R. Leemans, H.P. Bijl,M.E.M.C. Christianen, R.J.H.M. Steenbakkers, J.A. Langendijk (The Netherlands) 101
Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational studyM.E.M.C. Christianen, C. Schilstra, I. Beetz, C.T. Muijs, O. Chouvalova, F.R. Burlage, P. Doornaert, P.W. Koken, C. R. Leemans, R.N.P.M. Rinkel,M.J. de Bruijn, G.H. de Bock, J.L.N. Roodenburg, B.F.A.M. van der Laan, B.J. Slotman, I.M. Verdonck-de Leeuw, H.P. Bijl, J.A. Langendijk(The Netherlands) 107
Multivariate modeling of complications with data driven variable selection: Guarding against overfitting and effects of data set sizeA. van der Schaaf, C.-J. Xu, P. van Luijk, A.A. van�t Veld, J.A. Langendijk, C. Schilstra (The Netherlands) 115
Second cancer after radiotherapy, 1981–2007D. Bartkowiak, N. Humble, P. Suhr, J. Hagg, K. Mair, B. Polivka, U. Schneider, D. Bottke, T. Wiegel (Germany, Switzerland) 122
Out-of-field contributions for IMRT and volumetric modulated arc therapy measured using gafchromic films and compared to calculations usinga superposition/convolution based treatment planning systemF. Van den Heuvel, G. Defraene, W. Crijns, R. Bogaerts (Belgium) 127
Out-of-field dose studies with an anthropomorphic phantom: Comparison of X-rays and particle therapy treatmentsC. La Tessa, T. Berger, R. Kaderka, D. Schardt, C. Körner, U. Ramm, J. Licher, N. Matsufuji, C. Vallhagen Dahlgren, T. Lomax, G. Reitz, M. Durante(Germany, Japan, Sweden, Switzerland) 133
Contribution to normal tissue dose from concomitant radiation for two common kV-CBCT systems and one MVCT system used in radiotherapyA. Shah, E. Aird, J. Shekhdar (UK) 139
Important ESTRO dates I